ABUS — ARBUTUS BIOPHARMA CORP

Ownership history in XTX Topco Ltd  ·  11 quarters on record

This page tracks every 13F SEC filing in which XTX Topco Ltd reported a position in ARBUTUS BIOPHARMA CORP (ABUS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.11% (2022 Q2)
Avg. % of fund
0.02%
First filed
2021 Q3
Last filed
2025 Q3
Quarters held
11
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 11,364 -12,550 -52.5% 0.00% $52K $4.54
2025 Q2 REDUCED 23,914 -48,498 -67.0% 0.00% $74K $3.09
2025 Q1 ADDED 72,412 +19,831 +37.7% 0.01% $253K $3.49
2024 Q4 ADDED 52,581 +22,568 +75.2% 0.01% $172K $3.27
7 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    ABUS price (monthly, adj. close)

Other funds also holding ABUS

As of 2025 Q4 — sorted by position size

Whitefort Capital Management, LP 3Y 16.41% Rangeley Capital, LLC 3.36% ADAR1 Capital Management, LLC 1.89% Two Seas Capital LP 3Y 1.25% Western Standard LLC 3Y 7Y 1.13% STEMPOINT CAPITAL LP 0.81% BlackBarn Capital Partners LP 0.59% SHERBROOKE PARK ADVISERS LLC 3Y 0.35% AlphaCentric Advisors LLC 3Y 0.23% Murchinson Ltd. 3Y 0.21%
← Back to XTX Topco Ltd Holdings